Alkermes Restructures, Prioritizing CNS And Oncology And Cutting 160 Employees
The reorganization, which is expected to save $150m, will cement the company's transition from a drug delivery specialist to a drug developer, CEO Richard Pops said.
You may also be interested in...
Keeping Track: A Novel Approval For Fluorodopa F 18, A Tentative Approval For Vumerity, And A Missed Goal Date For Zilretta
The latest drug development news and highlights from our US FDA Performance Tracker.
Access to branded drugs has remained steady, but there has been less management across brands by commercial payers, according to an analysis of the I&I market access environment by Bernstein.